九强生物
(300406)
| 流通市值：53.76亿 | | | 总市值：74.26亿 |
| 流通股本：4.24亿 | | | 总股本：5.86亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,030,120,532.68 | 678,677,570.36 | 334,810,688.09 | 1,355,507,324.47 |
| 营业收入 | 1,030,120,532.68 | 678,677,570.36 | 334,810,688.09 | 1,355,507,324.47 |
| 二、营业总成本 | 645,168,526.93 | 431,318,772.74 | 217,562,849.44 | 929,773,807.64 |
| 营业成本 | 198,102,725.02 | 129,868,480.06 | 60,471,472.54 | 279,921,068.94 |
| 税金及附加 | 15,289,704.44 | 9,693,395.76 | 5,334,191.44 | 18,520,752.54 |
| 销售费用 | 185,563,879.35 | 126,637,669.74 | 70,780,689.37 | 271,336,755.67 |
| 管理费用 | 92,509,348.95 | 60,916,862.58 | 29,497,452.78 | 137,545,457.88 |
| 研发费用 | 122,015,078.46 | 82,965,789.32 | 40,550,434.48 | 181,731,734.42 |
| 财务费用 | 31,687,790.71 | 21,236,575.28 | 10,928,608.83 | 40,718,038.19 |
| 其中:利息费用 | 37,678,973.09 | 25,060,336.89 | 12,439,357.2 | 49,443,237.05 |
| 其中:利息收入 | 5,894,023.92 | 3,564,685.76 | 1,197,377.59 | 10,435,527.73 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 11,286,357.16 | 7,336,210.85 | 3,665,217.16 | 12,135,601.29 |
| 资产处置收益 | -817,243.42 | -350,135.75 | -77,063.71 | -2,872,916.43 |
| 资产减值损失(新) | 0 | 0 | 0 | -180,755,267.59 |
| 信用减值损失(新) | -21,253,502.35 | -19,010,611.25 | 0 | -26,585,394.26 |
| 其他收益 | 10,659,175.33 | 5,281,793.85 | 3,106,311.02 | 8,327,332.07 |
| 四、营业利润 | 384,826,792.47 | 240,616,055.32 | 123,942,303.12 | 235,982,871.91 |
| 加:营业外收入 | 338,849.06 | 274,872.19 | 46,413.88 | 1,941,614.63 |
| 减:营业外支出 | 575,922.59 | 346,816.98 | 4,378.53 | 1,672,347.72 |
| 五、利润总额 | 384,589,718.94 | 240,544,110.53 | 123,984,338.47 | 236,252,138.82 |
| 减:所得税费用 | 50,375,857.34 | 30,208,046.95 | 18,373,065.47 | 45,714,851.05 |
| 六、净利润 | 334,213,861.6 | 210,336,063.58 | 105,611,273 | 190,537,287.77 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 334,213,861.6 | 210,336,063.58 | 105,611,273 | 190,537,287.77 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 333,222,152.38 | 210,307,311.98 | 105,607,356.33 | 189,874,176.06 |
| 少数股东损益 | 991,709.22 | 28,751.6 | 3,916.67 | 663,111.71 |
| 扣除非经常损益后的净利润 | 325,095,307.18 | 206,177,640.16 | 102,997,864.98 | 186,068,047.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.57 | 0.36 | 0.18 | 0.32 |
| (二)稀释每股收益 | 0.57 | 0.36 | 0.18 | 0.32 |
| 八、其他综合收益 | -17,596,892.86 | -643,149.69 | -338,607.92 | -495,498.1 |
| 归属于母公司股东的其他综合收益 | -17,388,344.28 | -482,362.27 | -253,955.94 | -372,617.64 |
| 九、综合收益总额 | 316,616,968.74 | 209,692,913.89 | 105,272,665.08 | 190,041,789.67 |
| 归属于母公司股东的综合收益总额 | 315,833,808.1 | 209,824,949.71 | 105,353,400.39 | 189,501,558.42 |
| 归属于少数股东的综合收益总额 | 783,160.64 | -132,035.82 | -80,735.31 | 540,231.25 |
| 公告日期 | 2026-10-28 | 2026-08-22 | 2026-04-27 | 2026-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |